Knock down of SCD1 enhanced the percentage of dead cells in vehicle control treated cells but did not alter the abilities of drugs to kill tumor cells. Our data demonstrates that UM cells are killed by treatment with aramchol plus regorafenib plus metformin via enhanced autophagic flux and that this combination may have the potential to control UM tumors that have metastasized to the liver.

P=N/A, N=2560, Active, not recruiting, Daiichi Sankyo | Not yet recruiting --> Active, not recruiting

P1, N=32, Recruiting, Galmed Pharmaceuticals Ltd | Not yet recruiting --> Recruiting

Additionally, myeloid differentiation primary-response protein 88 (MYD88), TNF Receptor Associated Factor 6 (TRAF-6) and IL-6 were markedly reduced in the liver by EZE. Collectively, EZE may be a promising candidate in sepsis-related liver injury following further clinical studies.

P=N/A, N=6927, Completed, JW Pharmaceutical

P4, N=88, Active, not recruiting, JW Pharmaceutical

P=N/A, N=4400, Not yet recruiting, Yonsei University

Repurposed drugs such as flubendazole and the ezetimibe derivative L14-8, along with natural compounds including evodiamine and luteolin, demonstrate translational potential for ferroptosis induction. Collectively, ferroptosis represents a promising therapeutic vulnerability for precision treatment of advanced prostate cancer.

P=N/A, N=400, Active, not recruiting, Brigham and Women's Hospital | Trial completion date: Sep 2025 --> Jun 2026

P1, N=60, Not yet recruiting, Hanmi Pharmaceutical Company Limited

Our study identifies SCD1-mediated lipid remodeling as a key driver of enhanced membrane fluidity and metastatic potential in CM. Inhibition of SCD1 increases lipid saturation, reduces membrane fluidity, induces oxidative stress, and suppresses liver and lung metastasis. The MAFG-METTL14-SCD1 axis thus represents a critical regulator of CM progression, and combined therapeutic targeting with aramchol and S-HFD offers promising translational potential.

P1, N=32, Not yet recruiting, Galmed Pharmaceuticals Ltd